



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

11.02.2026

To,
The Manger [Listing]
The BSE Limited
The Secretary, Listing Department
Phirozejeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Scrip code: 530317

Dear Sirs/Madam,

Sub: Outcome of the Board Meeting

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, ('SEBI Listing Regulations'), we wish to inform you that the Board of Directors, at its meeting held today, i.e. on Wednesday, February 11, 2026, inter-alia, has considered and approved the following:

Financial Results:

- The Unaudited Financial Results for the Third quarter and nine months ended on 31st December, 2025 in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (copy enclosed).
- Limited Review Report for the quarter ended 31st December 2025 (copy enclosed).

Approval for Availing Short-Term Working Capital Term Loan

The Board approved availing a **Short-Term Working Capital Term Loan** from ICICI Bank Limited for an amount not exceeding ₹5.50 Crores.

Key terms:

- **Amount:** ₹550 Lakhs
- **Tenure:** 6 months
- **Repayment:** Bullet repayment at the end of tenure
- **Interest:** Monthly servicing
- **Purpose:** To meet additional working capital requirements for execution of new orders

The Board authorised the Directors to finalise terms and execute necessary documents with the Bank.

The Board Meeting Commenced at 03:30 P.M and concluded at 04:30 PM



GODAVARI DRUGS LIMITED

Regd. Off.: 'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

The above information will also be available on the website of the Company at www.godavaridrugs.com

Kindly take the above information on record and acknowledge.

Thanking You,
For Godavari Drugs Limited

Venkatesh Achanta
Company Secretary & Compliance Officer
Membership Number : A53326

GODAVARI DRUGS LIMITED

CIN : L24230TG1987PLC008016

Regd Office : " Mayfair" S.P. Road,, Secunderabad

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2025

Rs.in Lakhs

| Sl. No | Particulars | Quarter ended | | | Nine months ended | | Year ended |
|--------|---|----------------|----------------|----------------|-------------------|----------------|-----------------|
| | | 31.12.2025 | 30.09.2025 | 31.12.2024 | 31.12.2025 | 31.12.2024 | 31.03.2025 |
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | Revenue from operations | 2218.43 | 2664.94 | 2955.21 | 7264.50 | 8784.75 | 11335.01 |
| 2 | Other Income | 1.63 | 63.54 | 9.76 | 66.39 | 87.21 | 97.72 |
| 3 | Total Revenue from operations (1+2) | 2220.06 | 2728.48 | 2964.97 | 7330.89 | 8871.96 | 11432.73 |
| 4 | Expenses | | | | | | |
| | (a) Cost of materials consumed | 1664.11 | 2399.24 | 1958.82 | 5862.28 | 6351.18 | 8523.96 |
| | (b) Changes in inventories of finished goods & work-in-progress | -175.95 | -388.23 | 349.78 | -649.59 | 54.97 | -358.20 |
| | (c) Employee benefits expense | 157.66 | 144.28 | 98.35 | 437.61 | 362.69 | 502.81 |
| | (d) Depreciation & amortization expense | 61.20 | 60.37 | 64.43 | 182.00 | 177.61 | 244.76 |
| | (e) Finance Costs | 111.12 | 90.84 | 110.98 | 302.42 | 362.48 | 473.20 |
| | (f) Other Expenses | 324.87 | 309.85 | 290.48 | 876.76 | 1144.47 | 1483.66 |
| | Total expenses | 2143.01 | 2616.35 | 2872.84 | 7011.47 | 8453.40 | 10870.19 |
| 5 | Profit before exceptional Items and tax | 77.05 | 112.13 | 92.13 | 319.42 | 418.56 | 562.54 |
| 6 | Exceptional items | 25.13 | - | - | 25.13 | - | - |
| 7 | Profit before Tax (5-6) | 102.18 | 112.13 | 92.13 | 344.55 | 418.56 | 562.54 |
| 8 | Tax expense | -26.42 | -12.06 | -15.39 | -64.71 | -69.87 | -124.54 |
| 9 | Net Profit for the period (7-8) | 75.76 | 100.07 | 76.74 | 279.84 | 348.69 | 438.00 |
| 10 | Other Comprehensive Income | | | | | | |
| | Items that will not be reclassified to | | | | | | |
| | (i) profit or loss | - | - | - | - | - | - |
| | (ii) Income tax relating to Items that will not be reclassified to profit or loss | - | - | - | - | - | - |
| | Items that will be reclassified to profit | | | | | | |
| | (iii) or loss | - | - | - | - | - | - |
| | Income tax relating to Items that will | | | | | | |
| | (iv) be reclassified to profit or loss | - | - | - | - | - | - |
| | Total Other Comprehensive Income (Net of Tax) | - | - | - | - | - | - |
| 11 | Total Comprehensive Income (9+10) | 75.76 | 100.07 | 76.74 | 279.84 | 348.69 | 438.00 |
| 12 | Paid-up equity share capital (Face Value Rs. 10/- per share) | 753.05 | 753.05 | 753.05 | 753.05 | 753.05 | 753.05 |
| 13 | Other Equity | | | | | | 3581.56 |
| 14 | Earnings per share (of Rs. 10/- each) (not annualized) | | | | | | |
| | (a) Basic | 1.01 | 1.33 | 1.02 | 3.72 | 4.63 | 5.82 |
| | (b) Diluted | 1.01 | 1.33 | 1.02 | 3.72 | 4.63 | 5.82 |

Notes:

- 1) The above results , as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 11th February, 2026.
- 2) The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3) The format for un-audited quarterly results as prescribed in SEBI's Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5th July, 2016. Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS.
- 4) Corresponding figures in previous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED

Mohit Jaju

Wholetime Director & CFO

DIN: 03405414



Place: Secunderabad

Date : 11.02.2026

Independent Auditor's Review Report on Standalone unaudited Nine months and quarter ended 31.12.2025 financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


To,
The Board of Directors
Godavari Drugs Limited
Secunderabad.

We have reviewed the accompanying statement of unaudited standalone financial results of Godavari Drugs Limited (the Company) for the Nine months and quarter ended 31st December 2025 (the statement). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co.,
Chartered Accountants
FRN: 00278S



Ayyadevara Srinivas
Proprietor
ICAI Membership No. 028803
Hyderabad .February 11, 2026
UDIN: 26028803UPTPDQ9385

